🎀 GYN Oncology — 2026-W39

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Comparative effectiveness/registry study in JAMA Network Open examining how program-level adoption of neoadjuvant chemotherapy relates to long-term survival in advanced ovarian cancer. Offers real-world data that could inform institutional treatment-sequencing practices.

Narrative review in Cancer (Q1) summarizing the current role and limitations of checkpoint inhibitors across gynecologic cancers, including MMR-based selection in endometrial cancer and modest activity in ovarian cancer. Useful overview to contextualize when and why immunotherapy is or isn't used in these tumor types.

Narrative review in Cancers (Basel) summarizing checkpoint inhibitor use across gynecologic cancers including cervical, endometrial, ovarian, and gestational trophoblastic neoplasia. Highlights biomarker-driven patient selection (e.g., dMMR/MSI-H endometrial, PD-L1 CPS in ovarian) to guide when immunotherapy adds benefit.

Pharmacovigilance disproportionality analysis of FAERS data on mirvetuximab soravtansine in platinum-resistant ovarian cancer, published in J Gynecol Oncol. Identifies known and previously unrecognized safety signals (e.g., ocular toxicity, colitis, pulmonary fibrosis) that could inform monitoring and adverse event management.

Retrospective single-center cohort study in advanced epithelial ovarian cancer receiving first-line bevacizumab-chemotherapy, published in J Gynecol Oncol. Suggests higher bevacizumab dose intensity correlates with better response and PFS, offering a dosing nuance pending prospective validation.

Preclinical study combining high-throughput drug screening with murine and patient-derived xenograft models of olaparib-resistant high-grade serous ovarian cancer, published in Exp Hematol Oncol. Shows synergy between PARP and topoisomerase I inhibitors, suggesting a potential combination strategy to overcome PARPi resistance, though no clinical data yet exist.

Long-term (2-year) follow-up of a single-arm phase 2 trial in recurrent low-grade serous ovarian cancer, published in Gynecologic Oncology, evaluating avutometinib plus defactinib after prior platinum chemotherapy. Shows durable responses and manageable toxicity, particularly in KRAS-mutant tumors, reinforcing this combination as a potential option in this rare subtype.

Preclinical translational study developing an optimized L1CAM-targeted CAR-T construct tested in patient-derived xenograft models of ovarian and gastric cancer, published in J Immunother Cancer. Provides early proof-of-concept for a novel CAR-T design but no clinical trial data in patients yet.

Retrospective cohort study in stage I vulvar squamous cell carcinoma treated with surgery alone, published in Gynecologic Oncology. Shows HPV/p53 molecular subtyping stratifies recurrence and survival risk, which could help identify patients who may need closer surveillance or adjuvant treatment consideration.